2 recruiting, 1 completed, 1 enrolling by invitation, 1 not yet recruiting. 2 Not applicable, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 1, Enrolling by invitation 1 |
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Not yet recruiting 1 |
Follow RETT Syndrome With Proven MECP2 Mutation: new trials by email Literature Review of RETT Syndrome With Proven MECP2 Mutation trials Research Report on RETT Syndrome With Proven MECP2 Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome | Phase 2 / Phase 3 | Not yet recruiting | Fenix Innovation Group | 40 | 2027-07-01 | 2026-09-09 |
| Intensive Multimodal Neurorehabilitation Targeting Neuroplasticity in Pediatric Neurodevelopmental and Chromosomal Disorders Neurodevelopmental Disorders, Neurodevelopmental Disorders (NDD) | Recruiting | Healing Hope International | 100 | 2026-03-01 | 2026-03-25 | |
| Repurposing Mirtazapine in Rett Syndrome mirtazapine - RETT Syndrome With Proven MECP2 Mutation | Phase 2 | Recruiting | University of Trieste | 54 | 2025-07-09 | 2026-02-24 |
| GCB-002 in Treatment of Patients With Rett Syndrome GCB-002 - RETT Syndrome With Proven MECP2 Mutation | Not applicable | Enrolling by invitation | Genecombio Ltd. | 6 | 2024-11-11 | 2026-09-15 |
| Osteoporosis in RETT Syndrome biological markers and evaluation of the mineral density at the lumber spine using DEXA - RETT Syndrome With Proven MECP2 Mutation | Not applicable | Completed | Assistance Publique - Hôpitaux de Paris | 98 | 2009-12-10 | 2026-04-08 |
Rett Syndrome (2) · Autism Spectrum Disorder (1) · Brain Injuries, Traumatic (1) · Cerebral Palsy (1) · Chromosome Aberrations (1) · Cognitive Dysfunction (1) · Developmental Disabilities (1) · DiGeorge Syndrome (1) · Down Syndrome (1) · Emotional Regulation (1) · Fragile X Syndrome (1) · Genetic Diseases, Inborn (1) · Hypoxia-Ischemia, Brain (1) · Marijuana Abuse (1) · Neurodevelopmental Disorders (1)
Nervous System Diseases (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, X-Linked (3) · Heredodegenerative Disorders, Nervous System (3) · Intellectual Disability (3) · Mental Disorders (3) · Neurobehavioral Manifestations (3) · Neurologic Manifestations (3) · X-Linked Intellectual Disability (3) · Genetic Diseases, Inborn (2) · Musculoskeletal Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · 22q11 Deletion Syndrome (1) · Abnormalities, Multiple (1)
Biomarkers (1) · Mirtazapine (1)
Assistance Publique - Hôpitaux de Paris (1) · Fenix Innovation Group (1) · Genecombio Ltd. (1) · Healing Hope International (1) · University of Trieste (1)
Australia (1) · China (1) · France (1) · Italy (1) · United States (1)
Dr. Tina Casoglos-Adamopoulos, OT, OTD, BCP (1) · Enrico Tongiorgi, PhD (1)